What's Happening?
U.S. Senator Jerry Moran (R-Kan.) has introduced the federal SUSTAIN 340B Act, a bill designed to manage the 340B Drug Pricing Program. This legislation aims to allow covered entities to utilize contract pharmacies without a numerical limit, provided
each pharmacy has dispensed at least one covered outpatient drug in the preceding 12 months. The bill also seeks to prohibit manufacturers from restricting drug delivery to contract pharmacies or conditioning sales on claims data. Furthermore, it proposes to codify a statutory definition of 'patient' and tighten child-site eligibility requirements concerning ownership, financial integration, and Medicare provider-based rules. The Act also mandates annual reporting from covered entities on the use of program savings, charity care, and patient demographics, and requires the application of financial assistance policies at child sites and contract pharmacies. An independent claims-level data clearinghouse would be created to prevent duplicate Medicaid discounting, and the U.S. Department of Health and Human Services' sanction authority would be expanded, with the 340B rebate model pilot sunsetting within a year.
Why It's Important?
The introduction of the SUSTAIN 340B Act is significant for the U.S. healthcare landscape, particularly for hospitals and healthcare providers that rely on the 340B Drug Pricing Program. This program allows covered entities to purchase eligible outpatient drugs at discounted prices, using the savings to maintain or expand patient services and provide access to life-saving medications. The proposed legislation addresses concerns raised by healthcare providers regarding increasing demands from manufacturers for additional patient data beyond Health Resources and Services Administration requirements, which has led to increased administrative burdens and costs for hospitals. By allowing unlimited contract pharmacies and preventing manufacturers from restricting delivery or conditioning sales, the bill aims to ensure that these entities can continue to serve patients, especially in geographically diverse regions. The Act's provisions for transparency and accountability, such as annual reporting on savings use and patient demographics, could also enhance public trust and program integrity, while the expansion of sanction authority aims to provide stronger oversight.
What's Next?
The SUSTAIN 340B Act will now proceed through the legislative process in the U.S. Senate. The bill's provisions, particularly those related to contract pharmacies and manufacturer restrictions, are likely to be debated by various stakeholders, including pharmaceutical manufacturers, healthcare providers, and patient advocacy groups. The Special Committee on the 340B Drug Pricing Program has already examined the program's funding and impact, with members expressing support for the program and openness to adding transparency requirements, provided they apply to manufacturers as well as covered entities. Recommendations for the 2027 legislative session include introducing legislation similar to a previously failed bill (SB 284) with additional transparency language, and considering requirements to identify how 340B savings are used to benefit states like Kansas. The future of the 340B program will depend on the legislative progress of this Act and potential amendments or alternative proposals that may emerge.
Beyond the Headlines
The debate surrounding the 340B Drug Pricing Program and Senator Moran's proposed Act highlights a deeper tension within the U.S. healthcare system: balancing drug affordability and access for vulnerable populations with the financial interests of pharmaceutical manufacturers. The increasing demands for patient data from manufacturers, as noted by testifiers, raise questions about data privacy and the potential for manufacturers to use this information to their advantage. The Act's attempt to codify a statutory definition of 'patient' and tighten child-site eligibility reflects an ongoing effort to refine the program's scope and prevent potential abuses, while ensuring its intended beneficiaries are served. The emphasis on transparency, requiring covered entities to report on savings use and charity care, could set a precedent for greater accountability across federal healthcare programs. This legislative effort underscores the complex interplay between federal regulation, state-level healthcare needs, and the evolving dynamics of the pharmaceutical industry.
